April 1995
Volume 36, Issue 5
Free
Articles  |   April 1995
Corneal pharmacokinetics of topical clarithromycin.
Author Affiliations
  • R H Gross
    UCLA Ocular Inflammatory Disease Center, University of California at Los Angeles School of Medicine 90024-7003, USA.
  • G N Holland
    UCLA Ocular Inflammatory Disease Center, University of California at Los Angeles School of Medicine 90024-7003, USA.
  • S J Elias
    UCLA Ocular Inflammatory Disease Center, University of California at Los Angeles School of Medicine 90024-7003, USA.
  • R Tuz
    UCLA Ocular Inflammatory Disease Center, University of California at Los Angeles School of Medicine 90024-7003, USA.
Investigative Ophthalmology & Visual Science April 1995, Vol.36, 965-968. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R H Gross, G N Holland, S J Elias, R Tuz; Corneal pharmacokinetics of topical clarithromycin.. Invest. Ophthalmol. Vis. Sci. 1995;36(5):965-968.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To evaluate the pharmacokinetics of topically applied clarithromycin, a new macrolide antibiotic, at various concentrations in a rabbit model. METHODS: Clarithromycin in dosages of 10, 20, and 40 mg/ml was administered topically every 2 hours for 48 hours to three groups of 16 New Zealand albino rabbits. Both corneas were treated. Right corneas were deepithelialized with n-heptanol. At 6, 12, 24, and 48 hours, tissue concentrations were determined in four animals from each group. RESULTS: Tissue drug concentrations increased with drug dosage and duration of therapy. Drug concentrations were significantly higher at 48 hours than at 6 hours, 12 hours, and 24 hours for both epithelialized and deepithelialized eyes in the 20 mg/ml and 40 mg/ml treatment groups (all P < or = 0.0015). A steady state concentration was not achieved in any group. Tissue drug concentrations were higher in deepithelialized corneas for each dose after 6 hours, although differences were not significant (all P > 0.059). Highest mean drug concentration at 48 hours was 241 micrograms/g in animals receiving 40 mg/ml of clarithromycin. After 6 hours, tissue concentrations in some groups were above MIC90 for many Chlamydia sp., Streptococcus sp., and Staphylococcus sp., and by 12 hours, concentrations were greater than MIC90 in all groups for many nontuberculous mycobacteria. CONCLUSIONS: Topical clarithromycin achieves therapeutic levels in corneal tissue in a rabbit model. Clarithromycin might be a useful broad-spectrum antibiotic for topical use in humans.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×